Douglas P. Zipes MD
Distinguished Professor, Professor Emeritus of Medicine, Pharmacology and Toxicology, Emeritus Director of the Division of Cardiology and Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IndianaDr. Douglas P. Zipes is Distinguished Professor, Professor Emeritus of Medicine, Pharmacology and Toxicology, and Emeritus Director of the Division of Cardiology and Krannert Institute of Cardiology at Indiana University School of Medicine. He received his medical degree from Harvard Medical School and trained at Duke University Medical Center in medicine and cardiology. He joined Indiana University in 1970, became Distinguished Professor in 1994, and then Director of Cardiology (1995–2004).
Having published almost 1000 medical articles and 16 textbooks with multiple editions, Dr. Zipes is the recipient of numerous awards from the American Heart Association, the Heart Rhythm Society, the American College of Cardiology, and the European Society of Cardiology, among other professional societies and institutions.
He is past president of the American College of Cardiology and the Heart Rhythm Society, and past chair of the American Board of Internal Medicine. He is a fellow of the Heart Rhythm Society, American Heart Association, European Society of Cardiology. He is Master of the American College of Physicians and American College of Cardiology, and he is a member of the American Society for Clinical Investigation and the Association of American Physicians. In addition, Dr. Zipes retains honorary membership in the Cardiac Society of Australia and New Zealand, Argentine Society of Cardiology, Hungarian Society of Cardiology, and Israel Heart Society.
Recent Contributions to PracticeUpdate:
- Pulmonary Vein Isolation With Single Pulse Irreversible Electroporation
- Atrial Dysfunction in Patients With HFpEF and Atrial Fibrillation
- CineECG Enables RV Outflow Tract Localization of Electrical Substrate in Patients With Brugada Syndrome
- Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death
- Azithromycin Use and Cardiovascular Mortality
- Left Atrial Appendage Closure vs Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation
- Recurrence of Atrial Fibrillation After Catheter Ablation in the CABANA Trial
- Hybrid PET/MRI in Arrhythmic Mitral Valve Prolapse
- The Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in COVID-19
- QT Intervals in Patients With COVID-19 Treated With Hydroxychloroquine With or Without Azithromycin